Considering that ETV4 rearrangement is mutually exclusive with other oncogenic driver mutations in prostate cancer, the study of the molecular features, specific therapeutic targets, and potential drugs for ETV4 subtypes of prostate cancer are needed. The gene discussed is ETV4; the disease is prostate carcinoma.